A Pilot Study Assessing the Feasibility and Safety of Measuring Interstitial Fluid Pressure (IFP) in Patients With Advanced Malignant Melanoma Before Starting Systemic Treatment
Trial Snapshot
- Phase
- Not Applicable
- Status
- Withdrawn
- Sponsor
- M.D. Anderson Cancer Center
- Primary Endpoint
- Feasibility measured by proportion of patients in whom interstitial fluid pressure (IFP) can be measured
Study Overview
Brief Summary
The goal of this clinical research study is to learn about the side effects of measuring the tumor pressure in patients who have advanced melanoma and have not received chemotherapy. Researchers also want to learn if patients with a lower tumor pressure may respond better to chemotherapy.
Detailed Description
Tumor Pressure Testing:
If you are found to be eligible to take part in this study, the pressure in up to three tumors will be measured. Medical photography will also be used for documentation if needed.
This will be done in the melanoma outpatient clinic. You will be asked to lie down and the skin over the lesion will be cleaned with betadine (iodine) or a different cleaning agent if you are allergic to iodine. The skin over the lesion will then be numbed with anesthetic. A topical anesthetic is a local anesthetic that is used to numb the surface of a body part. Thirty minutes before the IFP measurement, an EMLA patch (Lidocaine 2.5% and Prilocaine 2.5%) will be applied on the surface of study. Your treating doctor may prescribe a pain drug to help with any discomfort the measurement may cause.
For the tumor measurement, the tip of a needle will be inserted in a skin lesion (similar to a biopsy needle). The needle is connected to a machine that reads the pressure inside the tumor. The measurement itself will take a few seconds. The whole process, including cleaning and numbing the lesion, will take about 3-4 minutes.
You will stay in the clinic and be monitored for side effects for about 1 hour following the tumor measurement.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with histologic confirmation of malignant melanoma and skin lesion, and/or subcutaneous metastases.
- •Males and Females >/= 18 years of age.
- •Subject is willing and able to comply with scheduled visits and other trial procedures.
- •Patients must be chemo-naive for malignant melanoma. Prior immunotherapy is allowed.
- •Must be scheduled for systemic chemotherapy within 3 weeks of measurements
- •Patient must have at least a one intact tumor or satellite lesion measuring >/= 10 mm in longest diameter.
- •Patients must sign and date an informed consent.
Exclusion Criteria
- •1. Major surgery or radiation therapy close to the area where tumor IPF will be measured, within 4 weeks of starting the study treatment.
- •2. Patients with the only melanoma skin lesions being localized in the area of the head and neck.
- •3. High risk of bleeding with platelets \ 2 times upper limit of normal or patients on any type of anticoagulation.
- •4. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation, or may interfere with the interpretation of study results, and in the judgment of the investigator or his designee would make the subject inappropriate for entry into this study.
- •5. Patients will be excluded if they are receiving biological agents only.
- •6. Pregnant or lactating females.
Arms & Interventions
IFP Measurement
Tumor interstitial fluid pressure (IFP) assessments
Intervention: Tumor Interstitial Fluid Pressure (IFP) assessments (Procedure)
IFP Measurement
Tumor interstitial fluid pressure (IFP) assessments
Intervention: Transducer-catheter SPC-320 + Amplifier (Device)
Outcomes
Primary Outcomes
Feasibility measured by proportion of patients in whom interstitial fluid pressure (IFP) can be measured
Time Frame: Baseline only + follow up 3 days after measurement
Secondary Outcomes
No secondary outcomes reported